Key result
Heterologous NVX-CoV2373 booster elicits a ~7-fold rise in ancestral neutralizing antibodies but weaker Omicron responses.
Why the study?
The immunogenicity and short-term durability of NVX-CoV2373 as a heterologous COVID-19 booster in adults primed with different vaccines were not fully characterized.
Does a single booster dose of NVX-CoV2373 improve binding and pseudovirus-neutralizing antibody responses in adults primed with Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines?
Does a single booster dose of NVX-CoV2373 improve binding and pseudovirus-neutralizing antibody responses in adults primed with Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines?
Heterologous boosting with the protein-based NVX-CoV2373 vaccine is immunogenic and safe, offering an acceptable alternative to mRNA or adenoviral-based boosters.
Answers are grounded in this paper and cite their sources.
Supports NVX-CoV2373 as a safe heterologous booster alternative; extends RCT evidence for protein subunit platforms after mRNA or adenoviral priming.
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.
No takes yet. Share an insight, caveat, or question.
Lyke et al. (2023) studied COVID-19 Vaccination (n=67). NVX-CoV2373 was evaluated on Pseudovirus neutralizing antibody (PsVNA) geometric mean fold rise against D614G at Day 29. A single heterologous booster dose of NVX-CoV2373 was well-tolerated and elicited a 6.4- to 7.8-fold rise in neutralizing antibody titers against the ancestral D614G strain, with lower responses against Omicron sub-lineages.
Synapse has enriched 10 related papers. Consider them for comparative context: